Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-12 02:10 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Study of AEB071 (a Protein Kinase C Inhibitor) in Patients With CD79-mutant Diffuse Large B-Cell Lymphoma
NCT01402440 · Novartis Pharmaceuticals · PHASE1 · terminated · last registry update 2020-12-19 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “Study terminated due to enrolment challenges and availability of other options for DLBCL patients. The termination is not a consequence of any safety concern.” | – | Registry record, Novartis Pharmaceuticals |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against PRKD3 within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2021-03-17Results posted on the registry: Novartis Pharmaceuticals, Midostaurin (NCT01883362)
- 2020-12-19Phase 3 first posted: University Hospital Heidelberg, Quizartinib + Treatment according to Physician's Choice (NCT04676243)
- 2020-12-17Also stopped (terminated): Novartis Pharmaceuticals, AEB071 + mycophenolic plus tacrolimus (NCT00555789)
- 2020-09-16Also stopped (terminated): Array Biopharma, now a wholly owned subsidiary of Pfizer, AEB071 + MEK162 (NCT01801358)
- 2020-05-01Results posted on the registry: Brenda Cooper, MD, midostaurin + azacitidine (NCT01093573)
- 2020-01-09Also stopped (withdrawn): Novartis Pharmaceuticals, HDM201 + cytarabine (NCT03760445)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision